Reasons to Retain Medtronic Stock in Your Portfolio Now
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
Medtronic Stock Is Still A Great "Buy"
Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 results with revenue up 5.25% YoY and expects organic revenue growth of 4.75%-5% for fiscal 2025. Medtronic's strategic acquisitions and focus on innovation and efficiency are expected to drive sustainable growth and improve margins over the next 1-3 years.
4 Dividend Stocks to Double Up on Right Now
You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now!
Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?
MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead
Robotic surgery used to be fodder for science fiction movies. Not anymore.
2 Healthcare Dividend Stocks to Hold for the Long Haul
Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run.
Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain
Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong.
Reasons to Retain Medtronic Stock in Your Portfolio Now
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins.
MDT Stock May Gain Following the Positive Data From Optimize PRO Study
Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research.
Should You Pick Medtronic Stock At $85?
Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and adjusted earnings of $1.26 per share, compared to the consensus estimates of $8.3 billion and $1.25, respectively.
MDT Stock Gains From FDA Approval for Its InPen App
Medtronic receives an FDA nod for its InPen app, which will help launch the company's Smart MDI system.
